

We claim:

5 1. The use of TNF antagonists for producing drugs for treating those septic disorders where the serum level of interleukin-6 increases in a measurement period of at least thirty minutes.

10 2. The use as claimed in claim 1, wherein the serum level of interleukin-6 is 500 pg/ml and above in the measurement period.

15 3. The use as claimed in claim 1, wherein the measurement period is 4 - 10 hours.

20 4. The use as claimed in claim 1, wherein an $F(ab')_2$ fragment of a monoclonal anti-TNF antibody is used as TNF antagonist.

25 5. A commercial pack comprising a TNF antagonist together with instructions for the use of this TNF antagonist for treating septic disorders where the serum level of IL-6 increases in a measurement period of at least thirty minutes.

30 6. A commercial pack as claimed in claim 5, wherein a monoclonal anti-TNF antibody is used as TNF antagonist.

35 7. A method for establishing whether a patient suffering from sepsis is to be treated with TNF antagonists, which comprises the following steps:

(a) determination of the serum level of interleukin-6 in the patient at a first time t_1

(b) determination of the serum level of interleukin-6 at a second time t_2 which is at least 30 minutes after the first time t_1 , and determination of the ratio

40
$$V = \frac{\text{IL-6 level } (t_2)}{\text{IL-6 level } (t_1)}$$

45 (c) treatment with TNF antagonists in the case where $V > 1$.

The use of TNF antagonists as drugs for treating septic disorders

5 Abstract

DML ab 

TNF antagonists are used to produce drugs for treating septic disorders where the serum level of interleukin-6 increases in a measurement period of at least thirty minutes.

10

15

20

25

30

35

40

45